Tag: time

Uklon Store marks the company’s entry into e-commerce, introducing a scalable, asset-light and margin-accretive revenue stream that supports diversification, improves monetization of the existing user base, and underpins long-term growth and shareholder value.

JERICHO, N.Y., June 11, 2026 (GLOBE NEWSWIRE) -- Kimco Realty^® (NYSE: KIM) today announced that its operating subsidiary, Kimco Realty OP, LLC (“Kimco OP”), priced its offering of $525,000,000 aggregate principal amount of 3.50% exchangeable senior notes due 2031 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering size was increased from the previously announced offering size of $500,000,000 aggregate principal amount of notes. Kimco Realty Corporation (“Kimco”) will fully and unconditionally guarantee the notes on a senior, unsecured basis. The issuance and sale of the notes are scheduled to settle on June 15, 2026, subject to customary closing conditions. Kimco OP also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $75,000,000 principal amount of notes.

Co-Founder and Chief Executive Officer Elias Sabo to Retire at Year End

New long-term share-based incentive programme

NEW YORK, June 11, 2026 (GLOBE NEWSWIRE) -- Terra Property Trust, Inc. (the “Company”) announced yesterday that it has extended the expiration date of its previously announced exchange offer (the “Exchange Offer”) to exchange all validly tendered unsecured 6.00% Senior Notes due June 30, 2026, issued by the Company (the “Existing Notes”) for a combination of (i) new 11.00% Senior Secured Notes due July 1, 2027 to be issued by the Company (the “Exchange Notes”) and (ii) cash. The Exchange Offer is being made pursuant to the Company’s Registration Statement on Form S-4 (File No. 333-295631) (as amended, the “Registration Statement”), which has been filed with the Securities and Exchange Commission (the “SEC”).

ZUG, Switzerland, June 11, 2026 – Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced an upcoming presentation at Clinical Trials at the Summit 2026, taking place on June 12-13, 2026, in Las Vegas, Nevada.